

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claim 1 (previously presented): A pharmaceutical preparation for treating rheumatic syndromes comprising: sulfur, mustard seed and a cupric salt.

Claim 2 (previously presented): The pharmaceutical preparation of claim 1, wherein the cupric salt is copper sulfate.

Claim 3 (previously presented): The pharmaceutical preparation of claim 2 further comprising chamomile.

Claim 4 (previously presented): The pharmaceutical preparation of claim 3 further comprising talc as a carrier substance.

Claim 5 (previously presented): The pharmaceutical preparation of claim 4 further comprising camphor.

Claim 6 (previously presented): The pharmaceutical preparation of claim 5 further comprising potassium iodate.

Claim 7 (previously presented): The pharmaceutical preparation of claim 1, wherein the preparation is in powder form.

Claim 8 (previously presented): The pharmaceutical preparation of claim 1 comprising the following volume concentrations:

| | |
|--|------------------------|
| sulfur: | 30-50% by weight; |
| camomile: | 0-10% by weight; |
| camphor: | 0-25% by weight; |
| mustard seed: | 0.5-2.5% by weight; |
| copper sulfate: | 0.05-0.3% by weight; |
| potassium iodate: | 0-0.15% by weight; and |
| talc making up the remainder up to 100% by weight. | |

Claims 9-15 (canceled).

Please add the following new claims:

Claim 16 (previously presented): A pharmaceutical preparation of claim 3, wherein the chamomile is chamomile flowers.

Claim 17 (previously presented): A process for producing a pharmaceutical preparation useful for the treatment of rheumatic syndromes, wherein the process comprises the steps of:

mixing components comprising talc and sulfur into a powder form; and
adding catalytic powder to the powder form;

wherein the catalytic powder is a pulverulent mixture comprising talc, mustard seed and copper sulfate.

Claim 18 (previously presented): The process of claim 17 wherein the components further comprise camphor.

Claim 19 (previously presented): The process of claim 18 wherein the components further comprise chamomile.

Claim 20 (previously presented): The process of claim 19, wherein the chamomile is chamomile flowers.

Claim 21 (previously presented): The process of claim 17, wherein the catalytic powder further comprises potassium iodate.

Claim 22 (previously presented): The process of claim 17, further comprising the step of blending the components and the catalytic powder.

Claim 23 (previously presented): A pharmaceutical preparation produced by claim 17, wherein the preparation is adapted to treat rheumatic syndromes.

Claim 24 (currently amended): A method for treating a disorder, wherein said method comprises the step of administering to a human the pharmaceutical

preparation of claim 1, and wherein the disorder is sciatica, muscular rheumatism, arthritis, phlebitis, excessively high or low blood pressure, paralysis deformans, paralysis post myelitis, poliomyelitis, paralysis cereбрalis, paralysis post nephritis vel uraemia, ~~paralysis postlaesion cause alicuia mechanicap~~paralysis following or induced by injury, lesions, surgical procedures or impact, eczema, or x-ray-induced burns.

Claim 25 (previously presented): A method of claim 24, further comprising the step of cutaneously administering the pharmaceutical preparation.

Claim 26 (previously presented): The method of claim 24, wherein the pharmaceutical preparation is in the form of a powder suitable for application on a sole of a foot.

Claim 27 (currently amended): The pharmaceutical preparation of claim 8, wherein the sulfur is present in a volume concentration of 30-40% by weight, ~~and wherein the camomile is present in a volume concentration of 5-10% by weight, and wherein the camphor is present in a volume concentration of 15-25% by weight, and wherein the mustard seed is present in a volume concentration of 1-1.5% by weight, and wherein the copper sulfate is present in a volume concentration of 0.1-0.15% by weight, and wherein the potassium iodate is present in a volume concentration of 0.05-0.1% by weight.~~